[go: up one dir, main page]

UY25436A1 - STATIN-MMP INHIBITOR COMBINATIONS - Google Patents

STATIN-MMP INHIBITOR COMBINATIONS

Info

Publication number
UY25436A1
UY25436A1 UY25436A UY25436A UY25436A1 UY 25436 A1 UY25436 A1 UY 25436A1 UY 25436 A UY25436 A UY 25436A UY 25436 A UY25436 A UY 25436A UY 25436 A1 UY25436 A1 UY 25436A1
Authority
UY
Uruguay
Prior art keywords
mmp inhibitor
statin
inhibitor combinations
combination
ldl
Prior art date
Application number
UY25436A
Other languages
Spanish (es)
Inventor
Newton Roger Schofield Y David
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY25436A1 publication Critical patent/UY25436A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una combinación de un compuesto de estatina,que se sabe que causa una reducción en los niveles plasmáticos de colesterol lipoproteínas de baja densidad (ldl),y un inhibidor de mmp,que reduce la ruptura de tejidos conectivos. La combinación es útil para tratar trastornos vasculares y prevenir la insuficiencia cardiaca.The invention relates to a combination of a statin compound, known to cause a reduction in plasma levels of low-density lipoprotein cholesterol (LDL), and an mmp inhibitor, which reduces the breakdown of connective tissues. The combination is useful for treating vascular disorders and preventing heart failure.

UY25436A 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS UY25436A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
UY25436A1 true UY25436A1 (en) 2001-10-25

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25436A UY25436A1 (en) 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS

Country Status (18)

Country Link
EP (1) EP1063991A1 (en)
JP (1) JP2002506818A (en)
KR (1) KR20010041916A (en)
AR (1) AR018113A1 (en)
AU (1) AU1591699A (en)
BR (1) BR9815745A (en)
CA (1) CA2309588A1 (en)
CO (1) CO5070670A1 (en)
GT (1) GT199900039A (en)
HN (1) HN1999000029A (en)
MY (1) MY140504A (en)
NZ (1) NZ505994A (en)
PA (1) PA8469001A1 (en)
PE (1) PE20000348A1 (en)
SV (1) SV1999000026A (en)
UY (1) UY25436A1 (en)
WO (1) WO1999047138A1 (en)
ZA (1) ZA992106B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636783T2 (en) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION
CZ294063B6 (en) * 1996-05-17 2004-09-15 Warner-Lambert Company Biphenyl sulfonamide, use thereof and pharmaceutical composition in which it is comprised
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.

Also Published As

Publication number Publication date
AU1591699A (en) 1999-10-11
GT199900039A (en) 2000-09-06
SV1999000026A (en) 2000-01-18
MY140504A (en) 2009-12-31
BR9815745A (en) 2000-11-14
ZA992106B (en) 1999-09-30
KR20010041916A (en) 2001-05-25
EP1063991A1 (en) 2001-01-03
HN1999000029A (en) 1999-09-29
WO1999047138A1 (en) 1999-09-23
CA2309588A1 (en) 1999-09-23
PE20000348A1 (en) 2000-05-22
PA8469001A1 (en) 2002-09-17
AR018113A1 (en) 2001-10-31
NZ505994A (en) 2003-10-31
CO5070670A1 (en) 2001-08-28
JP2002506818A (en) 2002-03-05

Similar Documents

Publication Publication Date Title
AR032403A1 (en) INHIBITOR COMBINATIONS (ES) OF STEROL ABSORPTION WITH BLOOD MODIFIER (ES) TO TREAT VASCULAR TABLES
ECSP074704A (en) INHIBITOR COMBINATIONS (S) OF STEROL ABSORPTION WITH BLOOD MODIFIER (S) TO TREAT VASCULAR TABLES
ES2188285T3 (en) COMBINATIONS OF INHIBITORS OF THE TRANSPORT OF ILEAL BILIAR ACIDS AND DERIVATIVES OF NICOTINIC ACID FOR CARDIOVASCULAR INDICATIONS.
UY25268A1 (en) INHIBITION OF LIPOPROTEIN OXIDATION
DK1427409T3 (en) Method for Treating or Preventing Vascular Inflammation Using One or More Sterol Absorption Inhibitors
BR0315597A (en) Low-dose processes for treating disorders where tnf (alpha) activity is harmful
UY25322A1 (en) THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS TO TREAT AND PREVENT INFLAMMATORY DISEASES AND ATEROSCLEROSIS
UY25299A1 (en) STATIN-CARBOXYALKYL ETHER COMBINATIONS
MXPA03006855A (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same.
EA199900837A1 (en) METHOD OF USING CYCLOOXIGENASE-2 INHIBITORS TO PREVENT CARDIOVASCULAR DISORDERS
BR9911440A (en) Composition for the prevention and / or treatment of osteoporosis and changes due to menopause syndrome
ES2189529T3 (en) INHIBITOR COMBINATIONS FOR THE TRANSPORT OF BILIAR ACIDS IN THE ILEON AND COMPLEXING AGENTS FOR CARDIOVASCULAR INDICATIONS.
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
EA200300953A1 (en) THERAPEUTIC COMBINATIONS FOR USE IN CARDIOVASCULAR AND INFLAMMATORY DISEASES
PT942751E (en) COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES CONTAINING ANTIODEPRESSIVE AND / OR INHIBITORS OF MONOAMINO-OXIDASE AND / OR VITAMIN B12 AND / OR PRECURSORS OR INDUCTORS OF NEUROTRANSMITTERS
CL2004000366A1 (en) USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
BR9814885A (en) Combination of an angiotensin converting enzyme inhibitor and a diuretic for the treatment of microcirculatory disorders
UY25436A1 (en) STATIN-MMP INHIBITOR COMBINATIONS
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
BR9713522A (en) Method of using cyclooxygenase-2 inhibitors as antiangiogenic agents.
TR200100901T2 (en) Catheter-based method of preventing or delaying revascularization
DK0885005T3 (en) Use of dehydroepiandrosterone and aromatase inhibitors in the manufacture of a medicament for the treatment of a relative and absolute androgen deficiency in men
EA199901043A1 (en) PHARMACEUTICAL TRANSFERASE INHIBITORS IN A COMBINATION WITH HMG-CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT
BR9712307A (en) Pyrazolinones for the treatment of weakened potency

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110104